Angelica Fasolo, MD, works as a clinician and a researcher in the Montabone Unit for New Drugs Development directed by Dr Luca Gianni at the Fondazione IRCCS “Istituto Nazionale dei Tumori” in Milan where her main tasks and responsibilities are the treatment of patients with breast cancer, management of patients included in clinical trials and development of new drugs.

In 2002, Angelica Fasolo graduated in medicine and surgery with full absolute marks and first-class honour at the Universita’ degli Studi in Milan with a dissertation on “New therapeutic outlooks in advanced colorectal cancer: Oxaliplatine”.  From 2002 to 2006 she trained at the School of Specialisation in Oncology of the Istituto Nazionale dei Tumori in Milan, Division of Medical Oncology 1 directed by Dr Luca Gianni.

In 2006, Angelica Fasolo achieved the Specialisation in Oncology with full absolute marks and first-class honours at the Universita’ degli Studi in Milan with the Thesis: “Phase I study associated with pharmacokinetic and pharmacodynamic investigations of the antivascular agent Exherin ™ given once a week in patients with solid tumours resistant to conventional therapies”.

Angelica Fasolo has gained experience in several clinical trials under Good Clinical Practice and is author and co-author of a number of articles appearing in leading journals such as Annals of Oncology.